{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:57:23Z","timestamp":1790841443175,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["24KFL091"],"award-info":[{"award-number":["24KFL091"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.intimp.2026.116473","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T19:31:29Z","timestamp":1773084689000},"page":"116473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pathogenic Th17 cells orchestrate mucosal inflammation and drive secondary loss of response to infliximab in inflammatory bowel disease: clinical and mechanistic evidence"],"prefix":"10.1016","volume":"176","author":[{"given":"Guomin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiemin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2026.116473_bb0005","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh","year":"2024","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.intimp.2026.116473_bb0010","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1007\/s10787-024-01508-w","article-title":"Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients","volume":"32","author":"Kamal","year":"2024","journal-title":"Inflammopharmacology"},{"issue":"6","key":"10.1016\/j.intimp.2026.116473_bb0015","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J. Crohns Colitis"},{"issue":"6","key":"10.1016\/j.intimp.2026.116473_bb0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","article-title":"Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and Meta-analysis","volume":"35","author":"Bots","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.intimp.2026.116473_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108081","article-title":"Anti-tumour necrosis factor \u03b1 antibodies and circulating lymphocyte phenotypes in inflammatory bowel disease","volume":"100","author":"Defendenti","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116473_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ibd\/izac199","article-title":"The pathogenicity and synergistic action of Th1 and Th17 cells in inflammatory bowel diseases","volume":"29","author":"Cao","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.intimp.2026.116473_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cell.2019.11.026","article-title":"Serum amyloid a proteins induce pathogenic Th17 cells and promote inflammatory disease","volume":"180","author":"Lee","year":"2020","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.intimp.2026.116473_bb0040","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00281-019-00733-8","article-title":"The pathogenicity of Th17 cells in autoimmune diseases","volume":"41","author":"Yasuda","year":"2019","journal-title":"Semin. Immunopathol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116473_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109682","article-title":"ROR\u03b1 is critical for mTORC1 activity in T cell-mediated colitis","volume":"36","author":"Chi","year":"2021","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.intimp.2026.116473_bb0050","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1093\/ecco-jcc\/jjaa083","article-title":"Intestinal CD14+ macrophages protect CD4+ T cells from activation-induced cell death via Exosomal membrane TNF in Crohn\u2019s disease","volume":"14","author":"Liu","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"1","key":"10.1016\/j.intimp.2026.116473_bb0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1443-9573.2007.00320.x","article-title":"Consensus on the management of inflammatory bowel disease in China in 2007","volume":"9","author":"Ouyang","year":"2008","journal-title":"J. Dig. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2026.116473_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116473_bb0065","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2004.02.070","article-title":"Optimizing anti-TNF treatment in inflammatory bowel disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"issue":"Pt 2","key":"10.1016\/j.intimp.2026.116473_bb0070","article-title":"Qingchang suppository ameliorates mucosal inflammation in ulcerative colitis by inhibiting the differentiation and effector functions of Th1 and Th17 cells","volume":"337","author":"Cao","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.intimp.2026.116473_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00781","article-title":"JNK pathway-associated phosphatase\/DUSP22 suppresses CD4(+) T-cell activation and Th1\/Th17-cell differentiation and negatively correlates with clinical activity in inflammatory bowel disease","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116473_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032696","article-title":"CD4 T-cell subsets and the pathophysiology of inflammatory bowel disease","volume":"24","author":"Gomez-Bris","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2026.116473_bb0085","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/WNR.0000000000002183","article-title":"Activation of the MyD88-JNK pathway promotes pathogenetic Th17 differentiation by induction of activin-a secretion and enhances experimental autoimmune encephalomyelitis","volume":"36","author":"Jin","year":"2025","journal-title":"Neuroreport"},{"key":"10.1016\/j.intimp.2026.116473_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112339","article-title":"Enteroendocrine cells regulate intestinal homeostasis and epithelial function","volume":"593","author":"Nwako","year":"2024","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.intimp.2026.116473_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13045","article-title":"EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance","volume":"7","author":"Jiang","year":"2016","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.intimp.2026.116473_bb0100","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2020.12.010","article-title":"The TGF-\u03b2 superfamily cytokine Activin-A is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation","volume":"54","author":"Wu","year":"2021","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.intimp.2026.116473_bb0105","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.immuni.2018.09.004","article-title":"RAS P21 protein activator 3 (RASA3) specifically promotes pathogenic T helper 17 cell generation by repressing T-Helper-2-cell-biased programs","volume":"49","author":"Wu","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.116473_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01177","article-title":"Differential pathogenic Th17 profile in mesenteric lymph nodes of Crohn\u2019s disease and ulcerative colitis patients","volume":"10","author":"Bsat","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2026.116473_bb0115","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/ecco-jcc\/jjy051","article-title":"Pathogenicity of in vivo generated intestinal Th17 lymphocytes is IFN\u03b3 dependent","volume":"12","author":"Nizzoli","year":"2018","journal-title":"J. Crohns Colitis"},{"issue":"9","key":"10.1016\/j.intimp.2026.116473_bb0120","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1097\/MIB.0000000000000121","article-title":"IL-17A alone weakly affects the transcriptome of intestinal epithelial cells but strongly modulates the TNF-\u03b1-induced expression of inflammatory mediators and inflammatory bowel disease susceptibility genes","volume":"20","author":"Friedrich","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.intimp.2026.116473_bb0125","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1136\/gutjnl-2019-318483","article-title":"Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells","volume":"69","author":"Powell","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.intimp.2026.116473_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12865-019-0322-z","article-title":"Subsets of mononuclear phagocytes are enriched in the inflamed colons of patients with IBD","volume":"20","author":"Liu","year":"2019","journal-title":"BMC Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116473_bb0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/glia.20611","article-title":"Myelin-phagocytosing macrophages in isolated sciatic and optic nerves reveal a unique reactive phenotype","volume":"56","author":"van Rossum","year":"2008","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.intimp.2026.116473_bb0140","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05058-1","article-title":"Predictive biomarkers for anti-TNF alpha therapy in IBD patients","volume":"22","author":"Kumar","year":"2024","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116473_bb0145","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s10620-011-1780-1","article-title":"Th1 responses are more susceptible to infliximab-mediated immunosuppression than Th17 responses","volume":"56","author":"Kanayama","year":"2011","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116473_bb0150","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1136\/gutjnl-2017-315671","article-title":"Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn\u2019s disease","volume":"68","author":"Schmitt","year":"2019","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.intimp.2026.116473_bb0155","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/ecco-jcc\/jjad119","article-title":"An intestinal Th17 subset is associated with inflammation in Crohn\u2019s disease and activated by adherent-invasive Escherichia coli","volume":"17","author":"Paroni","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"11","key":"10.1016\/j.intimp.2026.116473_bb0160","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.it.2021.09.005","article-title":"ROR\u03b3t protein modifications and IL-17-mediated inflammation","volume":"42","author":"Kumar","year":"2021","journal-title":"Trends Immunol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:12:06Z","timestamp":1790838726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926003176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":32,"alternative-id":["S1567576926003176"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116473","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenic Th17 cells orchestrate mucosal inflammation and drive secondary loss of response to infliximab in inflammatory bowel disease: clinical and mechanistic evidence","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116473"}}